Public Companies
Locust Walk Framework for Supporting Public Companies
Private biotech companies need efficient strategies and funding from equity capital or strategic partnerships to move forward. Locust Walk offers comprehensive support in corporate strategy, sell-side partnerships, and product expansion.
Locust Walk’s framework ensures that biotech companies can strategically develop, optimize partnerships, and expand their products for sustainable growth.
Corporate Strategy
- Core vs. Non-core Programs: Focus based on therapeutic area and technology.
- Financing & Development Strategy: Assess financing capabilities and identify pipeline gaps.
Sell-Side Partnerships
- Core Programs: Choose between M&A and licensing for monetization.
- Non-core Programs & Partner Universe: Monetize non-core opportunities and connect with optimal partners.
Product Expansion
- Strategic Priorities & Attractive Targets: Identify expansion areas and promising assets or companies.
- Valuation, Deal Structure & Client Positioning: Accurately value assets, structure efficient deals, and effectively position the company to potential partners.
Corporate Strategy
- Core vs. Non-core Programs: Focus based on therapeutic area and technology.
- Financing & Development Strategy: Assess financing capabilities and identify pipeline gaps.
Sell-Side Partnerships
- Core Programs: Choose between M&A and licensing for monetization.Core Programs: Choose between M&A and licensing for monetization.
- Non-core Programs & Partner Universe: Monetize non-core opportunities and connect with optimal partners.
Product Expansion
- Strategic Priorities & Attractive Targets: Identify expansion areas and promising assets or companies.
- Valuation, Deal Structure & Client Positioning: Accurately value assets, structure efficient deals, and effectively position the company to potential partners.
How Locust Walk Engages with Public Biotech Companies
Company Corporate and Portfolio Strategy
- Develop portfolio strategy for optimal program prioritization.
- Advise on asset externalization and partnering strategy.
- Develop portfolio strategy for optimal program prioritization.
- Advise on asset externalization and partnering strategy.
Early Platform Collaborations
- Identify partnerships for validation and non-dilutive funding.
- Create pitch materials and support deal structuring and valuation.
- Identify partnerships for validation and non-dilutive funding.
- Create pitch materials and lead or support deal process, structuring, and valuation.
Externalizing Core and Non-Core Assets
- Conduct valuations and commercial assessments for BD processes.
- Lead or support global and regional deal processes.
- Conduct valuations and commercial assessments for BD processes.
- Lead/support global and regional deal processes.
Accessing External Assets and Capabilities to Build Pipeline
- Execute buy-side screens and due diligence.
- Offer options for licensing, co-development, and M&A with detailed valuation modeling and deal structure advice.
- Execute buy-side screens and due diligence.
- Offer structured options for licensing, co-development, and M&A with detailed valuation modeling.
Locust Walk is committed to strategic and operational excellence, helping public biotech companies navigate complex business landscapes and achieve sustainable growth.
- How Locust Walk Engages with Public Biotech Companies
Company Corporate and Portfolio Strategy
- Develop portfolio strategy for optimal program prioritization.
- Advise on asset externalization and partnering strategy.
Early Platform Collaborations
- Identify partnerships for validation and non-dilutive funding.
- Create pitch materials and lead or support deal process, structuring, and valuation.
Externalizing Core and Non-Core Assets
- Conduct valuations and commercial assessments for BD processes.
- Lead or support global and regional deal processes.
Accessing External Assets and Capabilities to Build Pipeline
- Execute buy-side screens and due diligence.
- Offer options for licensing, co-development, and M&A with detailed valuation modeling and deal structure advice.
Supporting Public Companies
Private biotech companies must have an efficient strategy and will need equity capital or funding from strategic partnerships to move forward.
Engaging with Public Biotech Companies
